Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Christopher P. Cannon; Steen Husted; Robert A. Harrington; Benjamin M. Scirica; Håkan Emanuelsson; Gary Peters; Robert F. Storey

doi:10.1016/j.jacc.2007.07.053

Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Authors: Christopher P. Cannon, Steen Husted, Robert A. Harrington, Benjamin M. Scirica, Håkan Emanuelsson, Gary Peters, Robert F. Storey - Journal of the American College of Cardiology 2007 cited by 495

Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome | Litlas